Mitochondrial Research Panel

The Mitochondrial Research Panel is a three-vial set containing MOTS-c (10 mg), SS-31 (10 mg) and NAD+ (500 mg). MOTS-c is a peptide encoded in mitochondrial DNA; SS-31 is a synthetic peptide associating with the inner mitochondrial membrane; NAD+ is a dinucleotide coenzyme, not a peptide. The panel spans signal, membrane and substrate rather than representing a single mechanism.

Key Takeaways

• The Mitochondrial Research Panel contains MOTS-c at 10 mg, SS-31 at 10 mg and NAD+ at 500 mg, supplied lyophilized.
• NAD+ is a dinucleotide coenzyme rather than a peptide; it contains no amino acids and no peptide bonds.
• The three compounds represent three levels of mitochondrial function — a regulatory signal, a membrane environment, and a redox substrate.
• The masses are not matched and cannot meaningfully be, since a stoichiometric cofactor and a signalling peptide differ by orders of magnitude on a molar basis.
• Supplying NAD+ to a system is not equivalent to raising mitochondrial NAD+, because NAD+ pools are compartmentalised within the cell.
• No published study has examined these three compounds together, and all are supplied strictly for laboratory research.

What’s Included in This Research Panel

All three are supplied as lyophilized material with batch documentation.

NAD+ Is Not a Peptide

NAD+ — nicotinamide adenine dinucleotide — is a dinucleotide coenzyme. It consists of two nucleotides joined through a pyrophosphate bridge. It contains no amino acids, no peptide bonds, and belongs to a different molecular class than MOTS-c and SS-31 entirely.

This is stated first because NAD+ is routinely listed alongside research peptides, and search queries such as “NAD+ research peptide” reflect a misclassification that vendors reproduce rather than correct.

The distinction has practical consequences rather than being a terminological point:

• Purity means something different. Peptide purity assessment addresses truncated sequences, deletion products and oxidation. A dinucleotide’s impurity profile concerns different degradation products entirely.
• Storage failure modes differ. Peptides degrade through routes including oxidation, hydrolysis and aggregation. NAD+ is subject to pyrophosphate hydrolysis, a distinct chemical vulnerability.
• Mass comparison is misleading. A coenzyme functioning stoichiometrically is not comparable by mass to a signalling peptide.

A researcher who treats NAD+ as a peptide will apply the wrong specification checks to it. See also the glutathione and NAD+ comparison.

Why These Three Compounds Are Grouped Together

The three compounds relate to mitochondrial function at three different levels rather than through a shared mechanism.

These are three levels of description, not three parts of one mechanism. A signalling peptide, a membrane-associating peptide and a redox cofactor are studied with different methods and measured against different endpoints.

No synergy between the three has been established, and none is claimed here. The panel supplies materials relevant to a common research area, not a validated combination.

Where SS-31 and NAD+ relate to the same system

One connection is genuine and worth stating precisely.

NAD+ and its reduced form NADH are the electron donors feeding Complex I of the electron transport chain. That complex is embedded in the inner mitochondrial membrane — the same membrane whose organisation involves cardiolipin, the lipid SS-31 is studied for associating with.

So the two compounds relate to one system from different angles: SS-31 concerns the membrane environment in which the chain sits, NAD+ concerns the substrate supply feeding it. That describes a shared subject, not a demonstrated interaction.